| Literature DB >> 33642870 |
Roushan Liu1, Jian Zhang2, Xiaoli Du3, Yingying Lv1, Xiangyu Gao1, Yanyan Wang1, Junrui Wang1.
Abstract
PURPOSE: This study investigates the phenotypic and genotypic resistance features of OS-MRSA clinical isolates and their distinctive sensitivities to oxacillin.Entities:
Keywords: heterogeneous resistance; molecular typing; oxacillin sensitive MRSA
Year: 2021 PMID: 33642870 PMCID: PMC7903957 DOI: 10.2147/IDR.S288991
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Primers for PCR Amplification in This Study
| Primers | Sequences (5’-3’) | Size (bp) |
|---|---|---|
| GTAGGTGGCAAGCGTTATCC | 228 | |
| CGCACATCAGCGTCAG | ||
| TCCAGATTACAACTTCACCAGG | 162 | |
| CCACTTCATATCTTGTAACG | ||
| GAAAAAAAGGCTTAGAACGCCTC | 718 | |
| GAAGATCTTTTCCGTTTTCAGC | ||
| ATCATTAGGTAAAATGTCTGGACATGATCCA | 433 | |
| GCATCAASTGTATTGGATAGCAAAAGC | ||
| TAA AGACGATCCTTCGGTGAGC | Variable | |
| CAGCAGTAGTGCCGTTTGCT |
Antimicrobial Susceptibility Features of 14 OS-MRSA Isolates
| Isolates | PEN | ERY | TCY | CLI | GEN | LVX | SXT | NIT | VAN | LNZ | RIF | DAP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OS-200 | R | R | R | S | S | S | S | S | S | S | S | S |
| OS-253 | R | R | R | S | S | S | S | S | S | S | S | S |
| OS-373 | R | R | I | R | S | S | S | S | S | S | S | S |
| OS-511 | R | R | R | S | S | S | S | S | S | S | S | S |
| OS-678 | R | I | R | S | S | R | S | S | S | S | S | S |
| OS-682 | R | R | R | R | R | S | R | S | S | S | S | S |
| OS-790 | R | R | R | R | S | S | S | S | S | S | S | S |
| OS-1050 | R | R | R | R | R | S | S | S | S | S | S | S |
| OS-1057 | R | R | S | S | S | S | S | S | S | S | S | S |
| OS-1059 | R | R | R | S | S | S | S | S | S | S | S | S |
| OS-1060 | R | I | S | I | S | S | S | S | S | S | S | S |
| OS-1061 | R | R | S | R | S | S | S | S | S | S | S | S |
| OS-1068 | R | R | I | S | S | S | S | S | S | S | S | S |
| OS-1502 | R | I | R | S | R | S | S | S | S | S | S | S |
| Resistant rates (%) | 100 | 78.57 | 64.29 | 35.71 | 21.43 | 7.14 | 7.14 | 0 | 0 | 0 | 0 | 0 |
Abbreviations: PEN, penicillin; ERY, erythromycin; TCY, tetracycline; CLI, clindamycin; Gen, gentamicin; LVX, levofloxacin; SXT, trimethoprim-sulfamethoxazole; NIT, nitrofurantoin; VAN, vancomycin; LNZ, linezolid; RIF, rifampicin; DAP, daptomycin; S, sensitive; I, intermediate; R, resistant.
Phenotypic Resistance Features of 14 OS-MRSA Isolates with Different Methods
| Isolates | VITEK-2 Oxacillin (μg/mL) | VITEK-2 Cefoxitin Screen (+/–) | BD Phoenix Oxacillin (μg/mL) | BD Phoenix Cefoxitin (μg/mL) | Cefoxitin Disc Diffusion (mm) | Oxacillin Broth Microdilution (μg/mL) | PBP2a Protein |
|---|---|---|---|---|---|---|---|
| OS-200 | 0.5 | - | 1 | 4 | 21 | 1 | - |
| OS-253 | 2 | - | 1 | 4 | 23 | 1 | + |
| OS-373 | ≤0.25 | - | ≤0.25 | ≤2 | 22 | 0.25 | - |
| OS-511 | ≤0.25 | - | 0.5 | ≤2 | 24 | 0.5 | + |
| OS-678 | 1 | - | 0.5 | 4 | 23 | 0.5 | + |
| OS-682 | 2 | - | 1 | 4 | 26 | 0.5 | - |
| OS-790 | ≤0.25 | - | 0.5 | ≤2 | 24 | 0.25 | - |
| OS-1050 | ≤0.25 | - | ≤0.25 | 4 | 27 | 0.25 | + |
| OS-1057 | 1 | - | 0.5 | 4 | 26 | 0.5 | + |
| OS-1059 | 0.5 | - | 1 | 4 | 24 | 0.25 | - |
| OS-1060 | ≤0.25 | - | ≤0.25 | ≤2 | 30 | 0.25 | - |
| OS-1061 | 0.5 | - | 1 | 4 | 24 | 0.5 | - |
| OS-1068 | 1 | - | 1 | 4 | 19 | 1 | - |
| OS-1502 | 1 | - | 1 | 4 | 21 | 0.5 | + |
Figure 1Molecular typing results of 14 OS-MRSA isolates.
Figure 2Population analysis profiles of 14 OS-MRSA, 1 MRSA isolate and 1 MSSA isolate. ●, oxacillin; ■, oxacillin+mupirocin.
Frequency of Heterogeneous Resistance and Expression of PBP2a Protein of 14 OS-MRSA Isolates
| Isolate | Primary Isolate | Highly Oxacillin-Resistant Subpopulations | Highly Oxacillin-Resistant Subpopulations | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Oxacillin MIC (μg/mL) | PBP2a | Frequency | Oxacillin MIC (μg/mL) | Frequency | PBP2a | Oxacillin MIC (μg/mL) | Frequency | PBP2a | |
| OS-200 | 1.0 | - | 10–5 | 64 | 10−9 | + | 128 | 10−9 | + |
| OS-253 | 1.0 | + | 10–8 | 16 | 10−9 | + | 32 | 10−9 | + |
| OS-373 | 0.25 | - | 10–8 | 64 | 10–8 | + | 256 | 10−9 | + |
| OS-511 | 0.5 | + | 10–7 | 256 | 10−9 | + | 256 | 10−9 | + |
| OS-678 | 0.5 | + | 10–7 | 256 | 10−9 | + | 32 | 10–8 | + |
| OS-682 | 0.5 | - | 10–8 | 512 | 10−9 | + | 512 | 10–8 | + |
| OS-790 | 0.25 | - | 10−9 | 4 | 10−9 | + | 128 | 10−9 | + |
| OS-1050 | 0.25 | + | 10−9 | 16 | 10−9 | + | 32 | 10−9 | + |
| OS-1057 | 0.5 | + | 10–5 | 128 | 10−9 | + | 256 | 10−9 | + |
| OS-1059 | 0.25 | - | 10–8 | 256 | 10–8 | + | 512 | 10−9 | + |
| OS-1060 | 0.25 | - | 10−6 | 256 | 10−9 | + | 512 | 10−9 | + |
| OS-1061 | 0.5 | - | 10−9 | 16 | 10−9 | + | 64 | 10−9 | + |
| OS-1068 | 1.0 | - | 10–8 | 256 | 10–8 | + | 512 | 10−9 | + |
| OS-1502 | 0.5 | + | 10–8 | 512 | 10–8 | + | 4 | 10−9 | + |
Notes: aOxacillin resistant subpopulations (≥4μg/mL) screened by PAP method (serial oxacillin); bThe subpopulations with the highest resistant level to oxacillin by PAP (serial oxacillin); cThe subpopulations with the highest resistant level to oxacillin by PAP (serial oxacillin plus 0.03μg/mL mupirocin).